Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 3Neuroendocrine Tumors 1Hypoxia 1

Interventions

Everolimus 7lutetium Lu 177 dotatate 4lanreotide 4Sunitinib 4Temozolomide 3Octreotide 3Nivolumab 3Magnetic Resonance Spectroscopy 3Fluorodeoxyglucose F18 3Capecitabine 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3copper dotatate CU-64 2amino-acid, glucose, and electrolyte solution 2Quality of Life 2FAPI-46 2veliparib 1tivozanib 1tislelizumab 1telotristat ethyl 1surufatinib 1romidepsin 1repotrectinib 1pralsetinib 1pembrolizumab 1pasireotide 1gallium Ga 68 dotatate 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × Tirapazamine × Gastrointestinal × Clear all
NCT02174549 2026-04-20

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Teclison Ltd.

Phase 1/2 Recruiting
25 enrolled
EndocrineGastrointestinalNET

Hypoxia, Carcinoma, Hepatocellular, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡